Retour au classement

Exponent, Inc. (EXPO)

NEUTRAL
IndustrialsEngineering & ConstructionUnited States

Fondamental

65

Prix

$69.78

Capitalisation boursière

$3.39B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilan & Liquidités

Chiffre d'affaires

$632M

12 derniers mois (au 03/07/2026)

Résultat net

$112M

12 derniers mois (au 03/07/2026)

Flux de trésorerie libre

$122M

Capitaux propres totaux

$390M

Passif total

$387M

Ratio de liquidité général

1.98

Couverture des intérêts

-

Dette/EBITDA

0.62

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

General caseJustement valorisé

Juste valeur

$63.65

Prix actuel

$69.78

Marge de sécurité

-9.6%

Fourchette de juste valeur

$45.42 - $81.89

Méthodes d'estimation

Analyst price target:$84.00
Discounted cash flow (DCF):$62.39
Earnings multiple (P/E):$59.46
Graham growth formula:$40.11
Earnings power value (EPV):$22.15
Justified P/B:$43.75
Dividend discount (Gordon):$29.62
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$60.80
Revenue multiple:Not enough data to compute it
Consensus des analystes:Achat fort (8B / 2H / 0S)
Dernière surprise sur les résultats:+6.95%

Indicateurs de valorisation

Ratio P/E

31.88

ROE

27.2%

Ratio P/B

11.66

P/FCF

31.00

Marge brute

-

ROIC

20.4%

Radar de rentabilité

Value Creation (Economic Moat)

ROIC

20.4%

WACC

8.1%

ROIC − WACC

+12.3 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Critères d'analyse fondamentale

Réussi (18)

  • EPS shows upward trend
  • Price CAGR 8.82%
  • ROIC 20.4%
  • Debt/Equity ratio
  • Operating Margin 20.2%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 27.9%
  • Revenue Growth 5Y 7.8%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 4.3%
  • Earnings Quality (OCF/NI) 1.06
  • Share Dilution -0.9%
  • Piotroski F-Score 5/9

Échoué (7)

  • EPS CAGR 2.16%
  • P/FCF 31.00
  • P/B Ratio 11.66
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 4.90
  • Net Margin Trend 17.7% vs 18.3%

Indisponible (3)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage

Score F de Piotroski

5/9

Signaux mixtes : certains domaines nécessitent attention

score
criteria

Qualité des bénéfices

1.06

Qualité élevée : bénéfices soutenus par la trésorerie

Dilution du capital

-0.9%

Rachat d'actions. Favorable aux actionnaires

Gouvernance

Équipe dirigeante

NomTitreÂge
Dr. Catherine Ford Corrigan P.E., Ph.D.CEO & Director56
Mr. Richard L. Schlenker Jr.Executive VP, Corporate Secretary & Director59
Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D.Group Vice President56
Dr. Joseph Rakow Ph.D.Group Vice President48
Dr. Joseph Sala Ph.D.Group Vice President48
Dr. John D. Pye P.E., Ph.D.President54
Dr. Bernard Ross P.E., Ph.D.Co-Founder & Principal Engineer-
Mr. Eric R. AndersonChief Financial Officer50
Ms. Gina FlynnVP of Legal & General Counsel-
Mr. Brian KundertChief Human Resources Officer50

Risque d'audit

9

Risque du conseil

2

Risque de rémunération

4

Risque droits des actionnaires

2

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Latest News

Recent headlines for EXPO, sourced from Markets Gazette.

No recent news for EXPO.